Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab effects on atherosclerotic disease burden (GLAGOV)
NCT01813422Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2013
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
A Phase 3 trial of evolocumab in coronary artery disease (CAD), hypercholesterolemia, sponsored by Amgen. Started Apr 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
coronary artery disease (CAD)hypercholesterolemia
Beyond the preview
Go deeper on NCT01813422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813422.